South Korea
· Delayed Price · Currency is KRW Prestige BioPharma Statistics
Total Valuation
KRX:950210 has a market cap or net worth of KRW 176.68 billion. The enterprise value is 210.20 billion.
| Market Cap | 176.68B |
| Enterprise Value | 210.20B |
Important Dates
The next estimated earnings date is Friday, September 19, 2025.
| Earnings Date | Sep 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:950210 has 12.02 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.02M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.59% |
| Owned by Insiders (%) | 30.40% |
| Owned by Institutions (%) | 0.09% |
| Float | 3.59M |
Valuation Ratios
The trailing PE ratio is 40.63.
| PE Ratio | 40.63 |
| Forward PE | n/a |
| PS Ratio | 20.40 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 9.65 |
| EV / Sales | 24.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.12 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.38 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.50 |
| Interest Coverage | -8.41 |
Financial Efficiency
Return on equity (ROE) is 0.04% and return on invested capital (ROIC) is -5.90%.
| Return on Equity (ROE) | 0.04% |
| Return on Assets (ROA) | -5.17% |
| Return on Invested Capital (ROIC) | -5.90% |
| Return on Capital Employed (ROCE) | -10.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 54 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.08 |
Taxes
In the past 12 months, KRX:950210 has paid 138.62 million in taxes.
| Income Tax | 138.62M |
| Effective Tax Rate | 39.83% |
Stock Price Statistics
The stock price has increased by +35.19% in the last 52 weeks. The beta is 1.08, so KRX:950210's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +35.19% |
| 50-Day Moving Average | 13,485.60 |
| 200-Day Moving Average | 14,443.20 |
| Relative Strength Index (RSI) | 41.95 |
| Average Volume (20 Days) | 141,446 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:950210 had revenue of KRW 8.66 billion and earned 21.79 billion in profits. Earnings per share was 361.82.
| Revenue | 8.66B |
| Gross Profit | 7.44B |
| Operating Income | -62.24B |
| Pretax Income | 348.07M |
| Net Income | 21.79B |
| EBITDA | -42.51B |
| EBIT | -62.24B |
| Earnings Per Share (EPS) | 361.82 |
Balance Sheet
The company has 213.27 billion in cash and 148.52 billion in debt, giving a net cash position of 64.75 billion or 5,387.47 per share.
| Cash & Cash Equivalents | 213.27B |
| Total Debt | 148.52B |
| Net Cash | 64.75B |
| Net Cash Per Share | 5,387.47 |
| Equity (Book Value) | 541.08B |
| Book Value Per Share | 1,473.67 |
| Working Capital | 66.32B |
Cash Flow
In the last 12 months, operating cash flow was -61.21 billion and capital expenditures -37.75 billion, giving a free cash flow of -98.97 billion.
| Operating Cash Flow | -61.21B |
| Capital Expenditures | -37.75B |
| Free Cash Flow | -98.97B |
| FCF Per Share | -8,234.01 |
Margins
Gross margin is 85.94%, with operating and profit margins of -718.46% and 251.52%.
| Gross Margin | 85.94% |
| Operating Margin | -718.46% |
| Pretax Margin | 4.02% |
| Profit Margin | 251.52% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KRX:950210 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.07% |
| Shareholder Yield | n/a |
| Earnings Yield | 12.33% |
| FCF Yield | -56.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KRX:950210 has an Altman Z-Score of -0.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.27 |
| Piotroski F-Score | 3 |